A new governmentally-funded consortium in the UK will focus on testing and validating novel ALS epigenetic biomarkers. The consortium is funded by the UK government jointly with UK’s innovation agency, Innovate UK, at a total amount of £1.26m ($1.92m). The consortium includes the biotechnology company Chronos Therapeutics, jointly with Oxford BioDynamics, a provider of healthcare services, and the University of Oxford. The consortium brings together the expertise, data and samples of Chronos with a proprietary biomarker discovery platform developed by Oxford Biodynamics to rapidly and precisely identify epigenetic signatures in patient blood samples. Jointly, the parties will aim to identify novel epigenetic diagnostic and prognostic biomarkers for ALS.
Click here to read more.